腎臟去神經市場機會、成長動力、產業趨勢分析和 2025 - 2034 年預測

2024 年全球腎臟去神經支配市場規模達到 11 億美元，預計在 2025 年至 2034 年期間複合年成長率將達到 28%。隨著對微創治療的需求激增，醫療技術的快速進步進一步推動了腎臟去神經支配解決方案的採用率。

高血壓，特別是難治性高血壓已成為全球面臨的重大健康挑戰。傳統治療方法通常無法為難治性高血壓患者帶來有效的結果，因此迫切需要創新療法。腎臟去神經支配術已成為治療高血壓的一種突破性的微創解決方案。在良好的臨床試驗結果的支持下，這項技術正在贏得醫療服務提供者和患者的信任，加速其廣泛應用。

腎臟去神經支配系統的技術進步，包括射頻消融和基於超音波的設備，顯著提高了手術安全性和患者預後。這些創新擴大了治療的可近性，為受無法控制的高血壓困擾的患者帶來了新的希望。此外，強調未治療的高血壓的風險和腎去神經支配的好處的宣傳活動在刺激需求方面發揮關鍵作用。

根據技術，市場分為基於射頻、基於超音波、基於微輸注和其他系統。 2024 年，射頻技術將佔據主導地位，其普及度預計將以 29.3% 的複合年成長率成長，到 2034 年將達到 72 億美元。廣泛的臨床研究及其廣泛的可用性（特別是在發展中地區）進一步加強了其市場領導地位。

從最終用途來看，醫院佔 2024 年總收入的 62.3%，鞏固了其作為市場主要貢獻者的地位。醫院提供先進的基礎設施、熟練的專業人員以及確保手術成功的基本影像和監測工具。此外，它們也是臨床試驗、研究和訓練的重要中心，加速了腎臟去神經支配尖端技術的採用。

光是美國腎臟去神經支配市場在 2024 年的價值就達到 4.072 億美元，預計到 2034 年的複合年成長率將達到 26.6%。優惠的報銷政策和對心血管健康項目的大量投資進一步促進了這一上升趨勢。此外，正在進行的臨床試驗和研究計劃繼續建立信任和認知，鞏固腎臟去神經支配作為高血壓管理變革解決方案的地位。

目錄

第 1 章：方法論與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業衝擊力
  • 成長動力
    • 高血壓和抗藥性高血壓盛行率不斷上升
    • 人們對微創手術的認知不斷提高
    • 腎臟去神經支配技術的進展
    • 臨床試驗結果良好，展現療效與安全性
  • 產業陷阱與挑戰
    • 對手術安全性和潛在併發症的擔憂
• 成長潛力分析
• 監管格局
• 技術格局
• 差距分析
• 波特的分析
• PESTEL 分析
• 未來市場趨勢
• 價值鏈分析

第4章：競爭格局

• 介紹
• 公司市佔率分析
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 策略儀表板

第 5 章：市場估計與預測：按技術，2021 - 2034 年

• 主要趨勢
• 基於射頻
• 基於超音波
• 基於微灌注
• 其他技術

第 6 章：市場估計與預測：按應用，2021 - 2034 年

• 主要趨勢
• 高血壓
• 慢性腎臟病
• 其他應用

第 7 章：市場估計與預測：按最終用途，2021 - 2034 年

• 主要趨勢
• 醫院
• 門診手術中心
• 專科診所

第 8 章：市場估計與預測：按地區，2021 - 2034 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第9章：公司簡介

• Abbott
• ABLATIVE SOLUTIONS
• Boston Scientific
• Johnson and Johnson
• Medtronic
• Otsuka
• Recor
• Symple Surgical
• TERUMO
• VENUS MEDTECH

The Global Renal Denervation Market reached USD 1.1 billion in 2024 and is poised to expand at a remarkable CAGR of 28% between 2025 and 2034. This growth is primarily driven by the rising prevalence of hypertension and the increasing incidence of drug-resistant cases. As demand for minimally invasive treatments surges, rapid advancements in medical technology are further propelling adoption rates of renal denervation solutions.

Hypertension, especially resistant hypertension, has become a critical global health challenge. Traditional treatments often fail to deliver effective outcomes for patients with drug-resistant hypertension, creating a pressing need for innovative therapies. Renal denervation has emerged as a groundbreaking, minimally invasive solution to manage high blood pressure. Supported by favorable clinical trial outcomes, this technology is gaining trust among healthcare providers and patients alike, accelerating its widespread adoption.

Technological advancements in renal denervation systems, including radiofrequency ablation and ultrasound-based devices, have significantly improved procedural safety and patient outcomes. These innovations have expanded treatment accessibility, offering new hope to patients who struggle with uncontrolled hypertension. Additionally, awareness initiatives highlighting the risks of untreated hypertension and the benefits of renal denervation are playing a pivotal role in boosting demand.

The market is segmented by technology into radiofrequency-based, ultrasound-based, micro-infusion-based, and other systems. Radiofrequency-based technology dominated the landscape in 2024, and its popularity is projected to grow at a CAGR of 29.3%, reaching USD 7.2 billion by 2034. Known for its safety, precision, and cost-effectiveness, radiofrequency technology delivers consistent results and remains the preferred choice for healthcare providers. Extensive clinical research and its widespread availability, particularly in developing regions, further strengthen its market leadership.

In terms of end use, hospitals accounted for 62.3% of the total revenue in 2024, cementing their role as key contributors to the market. Hospitals offer advanced infrastructure, skilled professionals, and essential imaging and monitoring tools that ensure successful procedures. Moreover, they serve as critical hubs for clinical trials, research, and training, accelerating the adoption of cutting-edge technologies in renal denervation.

The U.S. renal denervation market alone was valued at USD 407.2 million in 2024 and is forecast to grow at a CAGR of 26.6% through 2034. Rising healthcare expenditures related to hypertension management are driving the adoption of innovative treatment methods. Favorable reimbursement policies and significant investments in cardiovascular health programs further contribute to this upward trajectory. Additionally, ongoing clinical trials and research initiatives continue to build trust and awareness, solidifying renal denervation as a transformative solution for hypertension management.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of hypertension and drug-resistant hypertension
    • 3.2.1.2 Rising awareness about minimally invasive procedures
    • 3.2.1.3 Advancements in renal denervation technologies
    • 3.2.1.4 Favorable clinical trial outcomes showcasing efficacy and safety
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Concerns about procedural safety and potential complications
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technology landscape
• 3.6 Gap analysis
• 3.7 Porter's analysis
• 3.8 PESTEL analysis
• 3.9 Future market trends
• 3.10 Value chain analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Technology, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Radiofrequency based
• 5.3 Ultrasound based
• 5.4 Micro-Infusion based
• 5.5 Other technologies

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Hypertension
• 6.3 Chronic kidney disease
• 6.4 Other applications

Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Ambulatory surgical centers
• 7.4 Specialty clinics

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 Abbott
• 9.2 ABLATIVE SOLUTIONS
• 9.3 Boston Scientific
• 9.4 Johnson and Johnson
• 9.5 Medtronic
• 9.6 Otsuka
• 9.7 Recor
• 9.8 Symple Surgical
• 9.9 TERUMO
• 9.10 VENUS MEDTECH